Last reviewed · How we verify

NCT03645902: TOF-SWAN

Comparison Between TOF and SWAN Sequences in the Detection of Arterial Occlusion in Acute Ischemic Stroke Using MRI

Completed Last updated 24 August 2018
What this trial tests

trial testing Magnetic resonance imaging in Stroke, Acute in 34 participants. Completed in 31 December 2014.

Timeline
1 March 2014
Primary endpoint
31 July 2014
31 December 2014

Quick facts

Lead sponsorLille Catholic University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment34
Start date1 March 2014
Primary completion31 July 2014
Estimated completion31 December 2014

Drugs / interventions tested

Conditions studied

Sponsor

Lille Catholic University

Who can join

18 and older, any sex, with Stroke, Acute or Angiography. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Optimizing the MRI protocol in acute ischemic stroke remains a challenging issue. In this field, susceptibility-weighted sequences have proved their superiority over T2. Besides the strengthened susceptibility effect, enhanced susceptibility-weighted angiography (eSWAN) sequence provides also a time-of-flight (TOF) effect, allowing the exploration of the intracranial arterial circulation. The objective of this study is to compare eSWAN and 3D TOF, considered as the reference, in the detection of arterial occlusion in acute stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Magnetic resonance imaging

Trials testing the same drug.

Other recruiting trials for Stroke, Acute

Currently open trials in the same condition.

Other Lille Catholic University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03645902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing